- Home
- VFF vs IMAB Comparison
VFF vs IMAB Comparison
Compare VFF & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFF
- IMAB
- Stock Information
- Founded
- VFF 1989
- IMAB 2014
- Country
- VFF Canada
- IMAB United States
- Employees
- VFF N/A
- IMAB N/A
- Industry
- VFF
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- VFF
- IMAB Health Care
- Exchange
- VFF Nasdaq
- IMAB Nasdaq
- Market Cap
- VFF 87.5M
- IMAB 79.9M
- IPO Year
- VFF N/A
- IMAB 2020
- Fundamental
- Price
- VFF $0.78
- IMAB $0.97
- Analyst Decision
- VFF Strong Buy
- IMAB Strong Buy
- Analyst Count
- VFF 2
- IMAB 3
- Target Price
- VFF $1.20
- IMAB $8.00
- AVG Volume (30 Days)
- VFF 378.7K
- IMAB 270.1K
- Earning Date
- VFF 03-12-2025
- IMAB 03-13-2025
- Dividend Yield
- VFF N/A
- IMAB N/A
- EPS Growth
- VFF N/A
- IMAB N/A
- EPS
- VFF N/A
- IMAB N/A
- Revenue
- VFF $327,852,000.00
- IMAB $569,464.00
- Revenue This Year
- VFF $17.95
- IMAB N/A
- Revenue Next Year
- VFF $1.92
- IMAB N/A
- P/E Ratio
- VFF N/A
- IMAB N/A
- Revenue Growth
- VFF 16.74
- IMAB N/A
- 52 Week Low
- VFF $0.58
- IMAB $0.84
- 52 Week High
- VFF $1.62
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- VFF 54.44
- IMAB 46.51
- Support Level
- VFF $0.71
- IMAB $0.96
- Resistance Level
- VFF $0.81
- IMAB $1.04
- Average True Range (ATR)
- VFF 0.04
- IMAB 0.05
- MACD
- VFF 0.00
- IMAB -0.00
- Stochastic Oscillator
- VFF 62.46
- IMAB 36.36
About VFF Village Farms International Inc.
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The Company has identified four operating segments - Produce, Cannabis-Canada, Cannabis-U.S. and Energy. The company makes majority of its revenue from the Produce segment.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).